HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea
· Delayed Price · Currency is KRW
15,150
+390 (2.64%)
Mar 10, 2026, 11:50 AM KST
HLB Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2019 | FY 2018 | FY 2017 |
| Mar '26 Mar 9, 2026 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
| Market Capitalization | 207,264 | 75,194 | 58,507 | 80,206 |
| Market Cap Growth | -40.00% | 28.52% | -27.05% | - |
| Enterprise Value | 197,610 | 77,595 | - | - |
| Last Close Price | 14760.00 | 5430.00 | 4225.00 | 6420.00 |
| PE Ratio | 438.51 | 159.09 | - | - |
| PS Ratio | 5.74 | 2.08 | 2.85 | 5.16 |
| PB Ratio | 11.58 | 4.20 | 3.44 | 4.77 |
| P/TBV Ratio | 11.87 | 4.31 | 3.50 | 4.83 |
| P/OCF Ratio | 153.15 | 55.56 | - | - |
| EV/Sales Ratio | 5.47 | 2.15 | - | - |
| EV/EBITDA Ratio | 64.15 | 25.19 | - | - |
| EV/EBIT Ratio | 137.14 | 53.85 | - | - |
| Debt / Equity Ratio | 0.74 | 0.74 | 0.45 | 0.89 |
| Debt / EBITDA Ratio | 4.28 | 4.28 | - | - |
| Net Debt / Equity Ratio | -0.11 | -0.11 | -0.08 | 0.21 |
| Net Debt / EBITDA Ratio | -0.64 | -0.64 | 0.30 | -1.27 |
| Net Debt / FCF Ratio | 44.86 | 44.86 | 0.49 | -1.18 |
| Asset Turnover | 0.88 | 0.88 | 0.54 | - |
| Inventory Turnover | 3.27 | 3.27 | 3.13 | - |
| Quick Ratio | 1.01 | 1.01 | 0.94 | 1.01 |
| Current Ratio | 1.26 | 1.26 | 1.31 | 1.31 |
| Return on Equity (ROE) | 2.71% | 2.71% | -41.77% | - |
| Return on Assets (ROA) | 2.19% | 2.19% | -9.55% | - |
| Return on Capital Employed (ROCE) | 6.30% | 6.30% | -28.80% | -17.40% |
| Earnings Yield | 0.23% | 0.63% | -12.07% | -6.79% |
| FCF Yield | -0.02% | -0.06% | -4.91% | -3.77% |
| Buyback Yield / Dilution | -2.30% | -2.30% | -13.08% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.